Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung Cancer

Plain-language summary

This study aims to develop a model to predict how long the disease stays without progression (progression-free survival) after Erlotinib treatment in patients with non-small cell lung cancer. It included patients who received erlotinib (enrolled on ECOG-E3503) with Stage IIIB/IV or recurrent disease. It is an observational (non-phase) study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

ECOG-ACRIN Cancer Research Group

Intervention

gene mapping, polymorphism analysis, diagnostic laboratory biomarker analysis, immunohistochemistry staining method

Start date

4/13/2007

Estimated completion

4/13/2008

Related genes

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

DISEASE CHARACTERISTICS:

* Diagnosis of non-small cell lung cancer, including any of the following subtypes:

  * Adenocarcinoma
  * Squamous cell carcinoma
  * Bronchoalveolar carcinoma
  * Carcinoid
* Stage IIIB or IV or recurrent disease
* Must have received treatment with erlotinib hydrochloride on clinical trial ECOG-E3503

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics